All Posts Tagged With: "MYL"
(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
(AMGN) Stock Market News for Dec 15, 2010 – Market News
15Dec2010 | vitalstocks | 0 comments | Continued
(TEVA) Teva Pharmaceutical Industries Beats The Street on Earnings
Teva Pharmaceutical Industries’ (TEVA) third quarter earnings of $1.30 per American Depository Share (ADS) were above the Zacks Consensus Estimate of $1.27 and the year-ago earnings of 89 cents.
Teva’s...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(CEPH) Cephalon Reports Very Strong Quarterly Earnings
Cephalon, Inc. (CEPH) delivered another strong quarter with earnings coming at $2.14 per share, easily beating the Zacks Consensus Estimate of $1.79 and well above the year-ago earnings of $1.62.
Strong...
(SHPGY) Shire Drug ProAmatine’s Approval to be Withdrawn by US Food and Drug Administration
The US Food and Drug Administration (FDA) recently announced that it plans to withdraw the approval of Shire plc’s (SHPGY) ProAmatine. The drug is used to treat low blood pressure (orthostatic hypotension).
The...
(CEPH) Cephalon Files Lawsuit Against Apotex – Several Companies Challenging Nuvigil Patent
In a recent filing with the US Securities and Exchange Commission (SEC), Cephalon Inc. (CEPH) announced that it has filed a lawsuit in the US District Court in Delaware against Apotex Corp. and Apotex Inc....
(CEPH) Cephalon Second Quarter 2010 Earnings Report Beats The Street
Cephalon Inc. (CEPH) delivered another strong quarter with second quarter earnings coming in at $2.05 per share, six cents above the Zacks Consensus Estimate and well above the year-ago earnings of $1.44...
(TEVA) Teva Pharmaceutical Industries Second Quarter 2010 Earnings Tops Estimates
Teva Pharmaceutical Industries’ (TEVA) second quarter earnings of $1.08 per American Depository Share (ADS) was above the Zacks Consensus Estimate of $1.04 and the year-ago earnings of 83 cents. Teva’s...
(CEPH) Cephalon Second Quarter 2010 Earnings Preview
Cephalon Inc. (CEPH) is scheduled to report second quarter results on July 27, 2010 after the market closes. The current Zacks Consensus Estimate for the second quarter is $1.99 per diluted share, representing...
(FRX) Forest Laboratories Settles Patent Fight
Forest Laboratories Inc. (FRX) and partner Merz GmbH & Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(MYL) Mylan Earns FDA Approval for Generic Version of Valtrex
Recently, Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline’s (GSK)...
(MYL) Mylan First Quarter 2010 Earnings Scorecard
First Quarter Highlights
On April 29, Mylan (MYL) reported first quarter fiscal 2010 earnings per share (EPS) of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted...
(TEVA) Teva Pharmaceutical Industries Reports Earnings That Beat The Street
Teva Pharmaceutical Industries’ (TEVA) first quarter earnings of 91 cents per American Depository Share (ADS) was well above the Zacks Consensus Estimate of 89 cents and the year-ago earnings of 71 cents....
(MYL) Mylan’s Quarterly Earnings Tops Expectations
Mylan (MYL) reported first quarter earnings per share of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter 2010 earnings came in at 36 cents, a couple of cents above...
(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(CEPH) Cephalon Completes Aquisition of Generic Drug Company Mepha AG
Cephalon, Inc. (CEPH) recently announced the completion of its acquisition of Mepha AG, a privately-held Swiss generic drug company, for CHF 662.4 million (approximately $615.4 million). This acquisition...
(MYL) Mylan Earns FDA Approval For Laxative Candidate
Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for the generic version of Braintree Laboratories’ NuLytely, a laxative. The company is eligible to ship the product...
(CEPH) Cephalon Experiences Regulatory Setback
Cephalon, Inc. (CEPH) suffered a regulatory setback recently with its failure to receive outright approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for...
(TEVA) Teva Pharmaceutical Industries Wins Race for Ratiopharm
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced its second major acquisition in a span of two years. The company announced its intention to acquire Germany’s second largest generics producer,...
(MYL) Mylan Strengthens Drug Portfolio
Mylan Inc. (MYL) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs – Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively.
Following...
(SLXP) Salix Pharmaceuticals Focuses on Label Expansion
Salix Pharmaceuticals, Ltd. (SLXP) is slated to report fourth quarter as well as fiscal 2009 results on March 9. The current Zacks Consensus Estimate for the fourth quarter of 2009 is a loss of 14 cents....
($MYL) Mylan Beats Earnings Expectations – Outlook Robust
Mylan (MYL) reported fourth quarter earnings per share (EPS) of 33 cents, surpassing the Zacks Consensus Estimate of 30 cents and 26 cents in the prior-year period. For the full year 2009, EPS came in at $1.30,...
(TEVA) Teva Pharmaceutical Industries Misses Earnings by a Penny
Teva Pharmaceutical Industries’ (TEVA) fourth quarter earnings of 94 cents per American Depository Share (ADS) missed the Zacks Consensus Estimate by a cent. Earnings, however Incorporatedreased 18% from...
(TEVA) Teva Pharmaceutical Industries Ltd Amends Agreement
Teva Pharmaceutical Industries Ltd. (TEVA) recently amended its marketing and distribution agreement with Active Biotech for oral laquinimod, which is being developed for the treatment of relapsing-remitting...
(CEPH) Cephalon Enters Generics Market
Cephalon Inc. (CEPH) has recently signed a deal which should mark the company’s entry into the generics business. The company announced that it intends to acquire Mepha AG, a privately held Swiss generic...
(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(WPI) Watson Pharmaceuticals Sees 16 Analysts Raising Fourth Quarter Estimates
Watson Pharmaceuticals, Inc. (WPI) reports fourth-quarter results on February 23, with the current Zacks Consensus Estimate at 72 cents per share. Estimates appear to be modestly up, with one of the 16 analysts...